Rapamycin (Sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells

Journal of Clinical Investigation

Volumn 99, Issue 9, 1997, Pages 2094-2099

  Javier, Annabelle F ^a   Bata Csorgo, Zsuzsanna ^a   Ellis, Charles N ^a,b   Kang, Sewon ^a   Voorhees, John J ^a   Cooper, Kevin D ^c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

keratinocytes; PCNA; psoriasis

Indexed keywords

CYCLIN D1; CYCLINE; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; RAPAMYCIN; RHODAMINE B;

ADULT; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL; COLONY FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; T LYMPHOCYTE ACTIVATION;

EID: 0030912133     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119382     Document Type: Article

References (43)

1. Bata-Csorgo, Zs., C. Hammerberg, J.J. Voorhees, and K.D. Cooper. 1995. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95:317-327.
2. Jones, P.H., S. Harper, and P.M. Watt. 1995. Stem cell patterning and fate in human epidermis. Cell. 80:83-93.
3. Celis, J.E., and A. Cells. 1985. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc. Natl. Acad. Sci. USA. 82:3262-3266.
4. Bravo, R., and H. Macdonald-Bravo. 1987. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J. Cell Biol. 105:1549-1554.
5. Celis, J.E., P. Madsen, A. Celis, H.V. Nielsen, and B. Gesser. 1987. Cyclin (PCNA, auxiliary protein of DNA polymerase δ) is a central component of the pathway(s) leading to DNA replication and cell division. FEBS (Fed. Eur. Biochem. Soc.) Lett. 220:1-7.
6. Celis, J.E., and P. Madsen. 1986. Increased nuclear cyclin/PCNA antigen staining of non S-phase transformed human amnion cells engaged in nucleotide excision DNA repair. FEBS (Fed. Eur. Biochem. Soc.) Lett. 209:277-283.
7. Jaskulski, D., J.K. DeRiel, W.E. Mercer, B. Calabretta, and R. Baserga. 1988. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science (Wash. DC). 240:1544-1546.
8. Liu, Y.-C., R.L. Marraccino,. P.C. Keng, R.A. Bambara, E.M. Lord, W.-G. Chou, and S.B. Zain. 1989. Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle. Biochemistry. 28:2967-2974.
9. 1 cyclins. Cell. 73:1059-1065.
10. Dowdy, S.F., P.W. Hinds, K. Louie, S.I. Reed, A. Arnold, and R.A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell. 73:499-511.
11. Pines, J. 1995. Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res. 66:181-212.
12. Tam, S.W., A.M. Theodoras, J.W. Shay, G.F. Draetta, and M. Pagano. 1994. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 9:2663-2674.
13. Bata-Csorgo, Zs., K.D. Cooper, K. Kang, J.J. Voorhees, and C. Hammerberg. 1996. Differential expression suggesting different functions of D-type cyclins in normal human keratinocytes. J. Investig. Dermatol. 106:828. (Abstr.)
14. Bata-Csorgo, Zs., C. Hammerberg, J.J. Voorhees, and K.D. Cooper. 1993. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferalive population in psoriasis. J. Exp. Med. 178:1271-1281.
15. Valdimarsson,. H., B.S. Baker, I. Jonsdottir, and L. Fry. 1986. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol. Today. 7:256-259.
16. Dumont, F.J., M.J. Staruch, S.L. Koprak, M.R. Melino, and N.H. Sigal. 1990. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144:251-258.
17. Liu, J., J.D. Farmer, Jr., W.S. Lane, J. Friedman, I. Weissman, and S.L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:807-815.
18. Liu, J., M.W. Albers, T.J. Wandless, S. Luan, D.G. Alberg, P.J. Belshaw, P. Cohen, C. MacKintosh, C.B. Klee, and S.L. Schreiber. 1992. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry. 31:3896-3901.
19. Dumont, F.J., M.R. Melino, M.J. Staruch, S.L. Koprak, P.A. Fischer, and N.H. Sigal. 1990. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J. Immunol. 144:1418-1424.
20. Taylor, R.S., K.D. Cooper, J.T. Headington, V.C. Ho, C.N. Ellis, and J.J. Voorhees. 1989. Cyclosporine therapy for severe atopic dermatitis. J. Am. Acad. Dermatol. 21:580-583.
21. Duncan, J.I. 1994. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J. Investig. Dermatol. 102:84-88.
22. Gong, J., F. Traganos, and Z. Darzynkiewicz. 1993. Simultaneous analysis of cell cycle kinetics at two different DNA ploidy levels based on DNA content and cyclin B measurements. Cancer Res. 53:5096-5099.
23. Kim, L.T., S. Ishihara, C.-C. Lee, S.K. Akiyama, K.M. Yamada, and F. Grinnell. 1992. Altered glycosylation and cell surface expression of β1 integrin receptors during keratinocyte activation. J. Cell Sci. 103:743-754.
24. Lee, H.-H., W.-H. Chiang, S.-H. Chiang, Y.-C. Liu, J. Hwang, and S.-Y. Ng. 1995. Regulation of cyclin D1, DNA topoisomerase I, and proliferating cell nuclear antigen promoters during the cell cycle. Gene Expr. 4:95-109.
25. Baptist, M., J.E. Dumont, and P.P. Roger. 1993. Demonstration of cell cycle kinetics in thyroid primary culture by immunostaining of proliferating cell nuclear antigen: differences in cyclic AMP-dependent and -independent mitogenic stimulations. J. Cell Sci. 105:69-80.
26. Gazitt, Y., G.W. Erdos, and R.J. Cohen. 1993. Ultrastructural localization and fluctuation in the level of the proliferating cell nuclear antigen and myc oncoproteins in synchronized neurohlastoma cells. Cancer Res. 53:1899-1905.
27. cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest. Mol. Cell. Biol. 11:1185-1194.
28. cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J. Biol. Chem. 268: 3734-3738.
29. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. 81:323-330.
30. 1 to S transition in human T lymphocytes. Science (Wash. DC). 250:805-808.
31. Lees, J.A., K.J. Buchkovich, D.R. Marshak, C.W. Anderson, and E. Harlow. 1991. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO (Eur. Mol. Biol. Organ.) J. 10:4279-4290.
32. Marx, S.O., T. Jayaraman, L.O. Go, and A.R. Marks. 1995. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 76:412-417.
33. Terada, N., R.A. Franklin, J.J. Lucas, J. Blenis, and E.W. Gelfand. 1993. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J. Biol. Chem. 268:12062-12068.
34. Nevins, J.R. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (Wash. DC). 258:424-429.
35. Chellappan, S.P., S. Hiebert, M. Mudryj, J.M. Horowitz, and J.R. Nevins. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell. 65:1053-1061.
36. Hiebert, S.W., S.P. Chellappan, J.M. Horowitz, and J.R. Nevins. 1992. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 6:177-185.
37. Bagchi, S., R. Weinmann, and P. Raychaudhuri. 1991. The retinoblastoma protein copurifies with E2F-I, and E1A-regulated inhibitor of the transcription factor E2F. Cell. 65:1063-1072.
38. Price, D.J., J.R. Grove, V. Calvo, J. Avruch, and B.E. Bjerer. 1992. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (Wash. DC). 257:973-977.
39. Terada, N., J.J. Lucas, A. Szepesi, R.A. Franklin, K. Takase, and E.W. Gelfand. 1992. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem. Biophys. Res. Commun. 186: 1315-1321.
40. Calvo, V., M. Wood, C. Gjertson,T. Vik, and B.E. Bierer. 1994. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. Eur. J. Imtnunol. 24:2664-2671.
41. 1. J. Biol. Chem. 254:9317-9323.
42. Terada, N., K. Takase, P. Papst, A.C. Nairn, and E.W. Gelfand. 1995. Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. J. Immunol. 155:3418-3426.
43. Brooks, R.F. 1977. Continuous protein synthesis is required to maintain the probability of entry into S phase. Cell. 12:311-317.